Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
免疫不全マウス
Document Type and Number:
Japanese Patent JP6935383
Kind Code:
B2
Abstract:
An object of the present invention is to provide an immunodeficient mouse which is capable of eliminating effects of immune cells from the immunodeficient mouse against human antibodies and in which human cells are engrafted at high level.Deletion of a mouse FcgR gene from an NOG mouse results in a mouse that does not exhibit antibody-dependent cellular cytotoxic activity on tumors, and in the mouse, human cells can be engrafted at significantly higher level than that in the NOG mouse. Furthermore, by introducing the human IL-15 gene into the mouse and engrafting a human NK cell in the mouse, only human NK cells become effector cells to enable evaluation of ADCC activity.

Inventors:
Takeshi Takahashi
Ikumi Katano
Application Number:
JP2018217229A
Publication Date:
September 15, 2021
Filing Date:
November 20, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
Central Institute for Experimental Animals
International Classes:
A01K67/027; C12N5/10; C12Q1/02
Foreign References:
WO2016189799A1
WO2017127414A1
Other References:
GIRARD-PIERCE, K. R., et al.,A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation,BLOOD,2013年09月,Vol. 122, No. 10,p. 1793-1801
KATANO, I., et al.,Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse,SCIENTIFIC REPORTS,2017年12月08日,Vol. 7 :17230,DOI:10.1038/s41598-017-17442-7
KATANO, I., e t al.,NOG-FcgR KO hIL-15 Tg mice provide a highly sensitive assay system for ADCC activity of human NK cells,Cancer Research,Vol. 79, Issue 13, supplement,2019年07月,pp. LB-032,DOI: 10.1158/1538-7445.AM2019-LB-032
Attorney, Agent or Firm:
Masaki Hirota
Seiji Ozawa
Yusaku Tokai
Kazuhiro Matsuda
Yasunori Matsuhashi
Makoto Horiuchi
Masako Yamauchi
Shuichi Sonomoto
Akihiro Yamamura
Hiroyuki Tomita